TLR4 and melanoma: Another LCP-based mRNA vaccine, also encoding TRP-2, managed to infiltrate antigen-presenting cells (APCs) by phagocytosis, inducing vigorous T cell activation, and promoting toll-like receptor 4 (TLR4)-mediated signaling and inflammatory cytokine release when subcutaneously injected in melanoma murine models.